

Tchaikapharma High Quality Medicines Inc.
Consolidated Statement of financial position
as of 31 March 2025

	31.03.2025	31.12.2024
Non-current assets	BGN'000	BGN'000
Property, plant and equipment	32,804	33,304
Intangible Assets and Goodwill	3,689	2,836
Trade receivables	5,403	5,403
Non-current assets	41,896	41,543
Inventories	16,037	15,862
Trade and other receivables	73,684	70,823
Current tax assets	129	129
Cash and cash equivalents	99	140
Current Assets	89,949	86,954
Assets	131,845	128,497
Issued capital	91,800	91,800
Statutory reserve	13,097	13,097
Retained earnings	6,710	4,545
Equity	111,607	109,442
<i>Equity Attributable to owners of the parent company</i>	<i>111,607</i>	<i>109,442</i>
<i>Non-controlling interest in equity</i>	<i>-</i>	<i>-</i>
Long term borrowings	556	675
Deferred tax liabilities	1,198	1,198
Non-current provisions for employee benefits	268	268
Non-current liabilities	2,022	2,141
Trade and other payables	6,783	6,337
Short term borrowings	10,379	10,454
Current tax liabilities	1,054	123
Current liabilities	18,216	16,914
Liabilities	20,238	19,055
Equity and liabilities	131,845	128,497

Date of preparation: 23.05.2025

Executive director:

Biser Georgiev

Prepared by:

Petya Moneva

Tchaikapharma High Quality Medicines Inc.
Consolidated statement of comprehensive income
as 31 March 2025


	31.03.2025	31.03.2024
	BGN'000	BGN'000
Revenue	16,188	13,361
Other income	49	
Total income	16,237	13,361
Carrying amount of goods sold	(989)	(609)
Changes in inventories of finished products and work in progress	(290)	341
Materials and services	(8,960)	(8,255)
Personnel expenses	(2,594)	(2,270)
Depreciation / amortisation expenses	(707)	(622)
Other expenses	(171)	(136)
Finance income	11	4
Finance costs	(152)	(188)
Total expenses	(13,852)	(11,735)
Profit Loss before tax	2,385	1,626
Current tax expense income	(220)	(160)
Profit Loss	2,165	1,466
<i>Profit Loss attributable to owners of the parent company</i>	<i>2,165</i>	<i>1,466</i>
<i>Profit Loss attributable to non-controlling interests</i>	<i>-</i>	<i>-</i>
Other comprehensive income	2,165	1,466
<i>Profit Loss attributable to owners of the parent company</i>		
<i>Profit Loss attributable to non-controlling interests</i>		
Comprehensive income	2,165	1,466
<i>Profit Loss attributable to owners of the parent company</i>	<i>2,165</i>	<i>1,466</i>
<i>Profit Loss attributable to non-controlling interests</i>	<i>-</i>	<i>-</i>
Earnings per share / in BGN per 1 share /	0.02	0.02

Date of preparation: 23.05.2025

Executive director:


Biser Georgiev

Prepared by:


Petya Moneva

Tchaikapharma High Quality Medicines Inc.
Consolidated Cash flow statement
as of 31 March 2025

	31.03.2025	31.03.2024
	BGN'000	BGN'000
Cash flows from operating activities		
Receipts from sales of goods and rendering of services	11,047	10,019
Payments to suppliers for goods and services	(5,686)	(5,001)
Payments to and on behalf of employees	(2,564)	(2,311)
Income taxes paid classified as operating activities	(220)	(160)
Other cash payments from operating activities	(1,947)	(1,286)
Cash flows from used in operating activities	630	1,261
Cash flows from investing activities		
Purchase of other longterm assets classified as investing activities	(419)	(926)
Cash flows from used in investing activities	(419)	(926)
Cash flows from financial activities		
Dividends paid classified as financing activities	117	155
Proceeds from borrowings classified as financing activities	(121)	(157)
Repayments of borrowings classified as financing activities	(117)	(145)
Payments of lease liabilities classified as financing activities	(131)	(130)
Cash flows from used in financial activities	(252)	(277)
Increase/Decrease in cash and cash equivalents	(41)	58
Cash and cash equivalents	140	73
Cash and cash equivalents	99	131

Date of preparation: 23.05.2025

Executive director:

Biser Georgiev

Prepared by:

Petya Moneva

Tchaikapharma High Quality Medicines Inc.
Consolidated statement on changes in equity
as of 31 March 2025


	Issued capital <i>BGN'000</i>	Property plant and equipment revaluation on surplus <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings <i>BGN'000</i>	Equity abstract <i>BGN'000</i>	Equity Attributable to owners of the parent company <i>BGN'000</i>	Non- controlling interest in equity <i>BGN'000</i>
Balance as of 01.01.2024	84,500	4,369	8,431	7,701	105,101	105,101	
Profit Loss				4,490	4,490	4,490	
Other comprehensive income		(49)					
Comprehensive income		(49)		4,490	4,441	4,441	
Increase/Decrease through appropriation of retained earnings	7,300		347	(7,647)			
Total income expense	7,300		347	(7,647)			
Balance as of 31.12.2024	91,800	4,320	8,778	4,544	109,442	109,442	
Balance as of 01.01.2025	91,800	4,320	8,778	4,544	109,442	109,442	
Profit Loss				2,165	2,165	2,165	
Other comprehensive income							
Comprehensive income				2,165	2,165	2,165	
Increase/Decrease through appropriation of retained earnings							
Total income expense							
Balance as of 31.03.2025	91,800	4,320	8,778	6,709	111,607	111,607	

Date of preparation: 23.05.2025

Executive director:


Biser Georgiev

Prepared by:


Petya Moneva